Anemo Labs is developing an electronic nose that combines sensor technology and AI to detect disease-related compounds through smell, with an initial focus on non-invasive healthcare screening.
London-based deeptech startup Anemo Labs has raised £700,000 in pre-seed funding to develop its technology for
detecting disease-related compounds through smell. The round was led by Zinc
and SFC Capital, with additional support from Innovate UK.
Founded in 2025 by Koye Sodipo, Anemo
Labs is developing an electronic nose, or e-nose, that combines sensor hardware
HOUSTON, TX / ACCESS Newswire / May 18, 2026 / Ainos, Inc. (NASDAQ:AIMD, AIMDW) ("Ainos" or the "Company") today highlighted a…
Sampling patients' breath may save lives and emergency room resources
AI Nose Expands from Semiconductor Facilities into Frontline Healthcare Infrastructure HOUSTON, TX / ACCESS Newswire / June 1,…
Agscent’s smell technology is already boosting productivity for dairy farms. But its backers are targeting advances in health,…
Bengaluru startup eNLife Research develops AI-driven blood tests for early Alzheimer’s detection, making diagnostics affordable…
The Bengaluru deeptech startup is running early trials that combine dogs' sense of smell with brain-computer interfaces and AI,…
Can dogs sniff cancer? An Israeli co-founded AI startup thinks so
